Takeda Submits NDA for a Subcutaneous Formulation of Vedolizumab for Patients with Moderately to…
Takeda Pharmaceutical Company Limited announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare in Japan for a subcutaneous (SC)…
Read More...
Read More...
